AGREED bfost, lots of impatient fishes out there who are good at timing things within 1 second of predicated announcements based on chart movements lol :)
On the ITC matter well covered by Sonam/oneragman: This seems to be a jurisdictional case. Obviously AMRN testing the law around two big regulatory organisations (ITC/FDA). These things are no small matter as it would set major precedent. It is understandable this is taking more time than usual. Its a very big decision with big ramifications not only for Amarin. My personal view is there will be some communication between FDA and ITC behind closed doors and that in order for the FDA not to lose face or their jurisdictional precedence.. they might come out with some sort of policy where dietary supplements should not be used to treat medical conditions. That is, some policy restricting the amount of pure EPA dietary supplements on the market or the labels of dietary supplements (similar to the 2 recent lawsuits) or the max % amount of EPA in each pill where it crosses over from a DS to a medical product. Well I guess that's my personal hope (could be wrong) and that's why I agree with some others on here that chastising the FDA (BB) about the history of ANCHOR is really not such a bright idea.
One thing nobody has mentioned on here (very surprising) and I think would be a MAJOR positive for shareholders is a V price increase. We all know JT has said its a volume gain, but its obvious we got something good and there is going to be a lot of demand for V over the next few years. The data was so good, so much better than more expensive PCSK9s and I think the pharma-economic studies to come over next few months are going to give Amarin a great opportunity for a nice price increase next year. Supply VS Demand tells me doing this right now is a no-brainer.
ahhhhhh SAM, we all miss you today :)
PS watching week to week scripts is fun but I am only expecting scripts to really take off around Feb/March.
